- Home
- ABUS vs PRAX Comparison
ABUS vs PRAX Comparison
Compare ABUS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- PRAX
- Stock Information
- Founded
- ABUS 2005
- PRAX 2015
- Country
- ABUS United States
- PRAX United States
- Employees
- ABUS N/A
- PRAX N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- ABUS Health Care
- PRAX Health Care
- Exchange
- ABUS Nasdaq
- PRAX Nasdaq
- Market Cap
- ABUS 672.1M
- PRAX 599.7M
- IPO Year
- ABUS N/A
- PRAX 2020
- Fundamental
- Price
- ABUS $3.08
- PRAX $37.02
- Analyst Decision
- ABUS Strong Buy
- PRAX Strong Buy
- Analyst Count
- ABUS 4
- PRAX 10
- Target Price
- ABUS $5.50
- PRAX $116.50
- AVG Volume (30 Days)
- ABUS 827.5K
- PRAX 401.5K
- Earning Date
- ABUS 05-14-2025
- PRAX 05-02-2025
- Dividend Yield
- ABUS N/A
- PRAX N/A
- EPS Growth
- ABUS N/A
- PRAX N/A
- EPS
- ABUS N/A
- PRAX N/A
- Revenue
- ABUS $6,403,000.00
- PRAX $8,122,000.00
- Revenue This Year
- ABUS $14.57
- PRAX N/A
- Revenue Next Year
- ABUS $15.84
- PRAX $789.73
- P/E Ratio
- ABUS N/A
- PRAX N/A
- Revenue Growth
- ABUS N/A
- PRAX 270.02
- 52 Week Low
- ABUS $2.63
- PRAX $26.70
- 52 Week High
- ABUS $4.72
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- ABUS 39.99
- PRAX 49.16
- Support Level
- ABUS $2.94
- PRAX $35.41
- Resistance Level
- ABUS $3.42
- PRAX $40.01
- Average True Range (ATR)
- ABUS 0.18
- PRAX 2.32
- MACD
- ABUS -0.04
- PRAX 0.18
- Stochastic Oscillator
- ABUS 17.72
- PRAX 35.47
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.